ライフサイエンスコーパス: superiority

1 0.97; P<0.001 for noninferiority; P=0.02 for superiority).

2 0.97; P<0.001 for noninferiority; P=0.01 for superiority).

3 onfidence interval, 0.79 to 1.26; P=0.98 for superiority).

4 .56; 95% CI, 0.43 to 0.72; P=3.29x10(-6) for superiority).

5 %; P < .001 for inferiority and P = .006 for superiority).

6 nflammation that will enhance burn recovery (superiority).

7 group (P=0.01 for noninferiority, P=0.10 for superiority).

8 oup (P<0.001 for noninferiority, P=0.008 for superiority).

9 9; P=0.007 for noninferiority and P=0.16 for superiority).

10 onfidence interval, 0.74 to 0.99; P=0.04 for superiority).

11 nce in the key secondary outcome (P=0.08 for superiority).

12 isk, 0.41; 95% CI, 0.20 to 0.78; P=0.005 for superiority).

13 ; P<0.001 for noninferiority and P=0.005 for superiority).

14 int was found (13.1% vs. 16.3%; p = 0.43 for superiority).

15 roup (P<0.001 for noninferiority; P=0.85 for superiority).

16 .4; P<0.001 for noninferiority; P = 0.04 for superiority).

17 1.36; P=0.006 for noninferiority; P=0.87 for superiority).

18 placebo with respect to efficacy (P=0.06 for superiority).

19 r superiority; odds ratio, 0.73; P<0.001 for superiority).

20 gylated interferon and ribavirin) to achieve superiority.

21 e been approved without evidence of clinical superiority.

22 lysis met the prespecified stopping rule for superiority.

23 merely condemning them with an air of moral superiority.

24 ow-up although the study was not powered for superiority.

25 power preclude definitive conclusions about superiority.

26 itabine was achieved, we would then test for superiority.

27 quivalence because the study was powered for superiority.

28 onse rates (ORRs) were compared to determine superiority.

29 ddressed the fundamental assumption of tonal superiority.

30 al [CI], 0.32 to 0.95 [two-tailed P=0.04 for superiority]).

31 to -3.5%, P for noninferiority, <.001; P for superiority, .004).

32 We did non-inferiority (margin 7.5%) and superiority analyses in propensity score quintiles to ca

33 Noninferiority and inferiority-superiority analyses were used to interpret the differen

34 The primary evaluation of efficacy was a superiority analysis in the per-protocol efficacy popula

35 y noninferiority analysis and an exploratory superiority analysis of RIV4 over IIV4.

36 Superiority analysis showed significantly lower use of h

37 Superiority analysis was performed on the secondary outc

38 In a non-prespecified superiority analysis, we observed a 43% reduction in the

39 We demonstrate the superiority and consistency of this method for calculati

40 ndary end points were tested for statistical superiority and included change in HbA1c level, change i

41 of baseline plasma renin; but its margin of superiority and likelihood of being the best drug for th

42 re capture of prostate cancer deaths in both superiority and noninferiority trials.

43 nced albeit critical view of these claims of superiority and outlines a framework for the proper use

44 Five trials had a superiority and three had a noninferiority primary hypot

45 1% for DCB versus 83.2% for PTA, P=0.025 for superiority) and the primary patency rate was significan

46 delay (AVD), contributing to its hemodynamic superiority, and evaluated its applicability for AVD opt

47 Further research is needed to assess superiority, as well as generalizability and durability

48 he main reason to prefer colonoscopy was its superiority at finding polyps.

49 Results demonstrated SSC's superiority at localizing Wernicke's area.

50 of ridinilazole and also showing statistical superiority at the 10% level.

51 .4% [95% CI, .33% to 12.36%]), demonstrating superiority at the 5% significance level.

52 with bivalirudin versus heparin did not meet superiority because it did not result in significantly l

53 sher exact test was <.001, which crossed the superiority boundary (P = .0061), the data and safety mo

54 Randomized, parallel-group, superiority clinical trial of otherwise healthy infants

55 to aspirin; dual-antiplatelet therapy proved superiority compared with aspirin monotherapy for the pr

56 l procedure for each opicapone dose in which superiority compared with placebo in the full analysis s

57 ure met criteria for both noninferiority and superiority, compared with warfarin, for preventing the

58 100-mm visual analog scale [VAS] 4 times/d; superiority comparison) and pleurodesis efficacy at 3 mo

59 This superiority coupled with strong quantitative agreement w

60 TH concentrations over 26 weeks; it also met superiority criteria.

61 k (RADAR) is a novel methodology utilizing a superiority design and a 2-step process: (1) categorizin

62 ny phase 4 RCTs focused on efficacy (using a superiority design), contemporary phase 4 RCTs often are

63 azine, and prednisone (BEACOPPesc) and INRT (superiority design).

64 These two psychological treatments had no superiority effect compared with brief psychosocial inte

65 bolism, and cardiovascular death, as well as superiority for cardiovascular and all-cause mortality.

66 and GCD) to directed networks and show their superiority for comparing directed networks.

67 Results from single-centre trials showing superiority for DPPHR were not confirmed in the multicen

68 terim analysis and declared overall survival superiority for nivolumab over investigator's choice the

69 A pattern of superiority for olanzapine, clozapine, and risperidone w

70 Conclusion C20 and C25 did not demonstrate superiority for OS versus D75 in patients with chemother

71 nsity score analysis indicates a significant superiority for our composite outcome with TAVR compared

72 modeling work indicated that this high-voice superiority for pitch originates in the sensory peripher

73 Statistical and clinical superiority for the 30 mg/kg IV dose compared with the 3

74 r some vital rates, shifting the competitive superiority from small to large individuals resulted in

75 terval, 1.1 to 3.0; posterior probability of superiority, >0.999), and the rate of functional indepen

76 interval, 24 to 44; posterior probability of superiority, >0.999).

77 2D-based nanohybrids have shown unparalleled superiorities in the field of electrochemical biosensors

78 Secondary end points included superiority in achieving biochemical end points (>50% an

79 Results demonstrate its effectiveness and superiority in comparison to state-of-the-art approaches

80 Paclitaxel exhibits its superiority in drug penetration and accumulation, result

81 l call set comparison demonstrates its clear superiority in finding common indels among call sets.

82 a conventional palladium source shows their superiority in generating high TON's and TOF's.

83 en met the prespecified primary end point of superiority in mean VA gain compared with anti-VEGF mono

84 re slightly more complex to implement, their superiority in mortality-predictive abilities suggests t

85 prising 243,732 variants and demonstrate its superiority in removing noisy variants and conducting hy

86 al and theoretical studies, illustrating its superiority in stability and self-correction of synchron

87 imeprevir + sofosbuvir for 12 weeks achieved superiority in SVR12 rates versus the historical control

88 Superiority in SVR12 was assessed for simeprevir+sofosbu

89 e joint analysis of both data has showed its superiority in the biomedical field but is scarcely used

90 Both methods were consistent in showing no superiority in time encoding for low over high frequenci

91 e combination of the two treatments (to test superiority) in patients with heart failure and a reduce

92 The machine system's superiority is attributable to its ability to differenti

93 The only regimen to demonstrate survival superiority is platinum, fluorouracil, and cetuximab, a

94 r group difference) for both endpoints, then superiority (lower limit 95% CI >0%) if non-inferiority

95 After specifying the requirements for superiority, non-inferiority, and equivalence trials, we

96 entage points (rate ratio, 0.60; P<0.001 for superiority; odds ratio, 0.73; P<0.001 for superiority).

97 In spite of the superiorities of TMUPS, its adoption has been challenged

98 There was no apparent superiority of (18)F-FLT uptake in progressive lesions,

99 The superiority of (64)Cu-CBP7 was traced to a much higher m

100 Summary ROC curve demonstrated overall superiority of 3-T imaging, with or without intra-articu

101 roup, demonstrating both non-inferiority and superiority of 4F-PCC over plasma (difference 14.3%, 95%

102 roup, demonstrating both non-inferiority and superiority of 4F-PCC over plasma (difference 45.3%, 95%

103 Heterosis, the phenotypic superiority of a hybrid over its parents, has been demon

104 e architecture lacking Cand1 which indicates superiority of a system with exchange factor if substrat

105 r VA outcomes compared with bevacizumab, but superiority of aflibercept over ranibizumab, noted at 1

106 Evidence supporting the superiority of ALS over basic life support (BLS) is limi

107 To date, no trial has demonstrated the superiority of an iPET-driven strategy in DLBCL.

108 This clearly indicates the superiority of AnGDH over other conventionally used fung

109 Apart from ITT D28 assessment, superiority of ASAQ on ACPR was demonstrated.

110 Superiority of BBFC+TRAV over vehicle+TRAV was based on

111 Superiority of BBFC+TRAV over vehicle+TRAV was establish

112 r follow-up, we were not able to confirm the superiority of BEACOPP over ABVD in terms of PFS, mainly

113 bgroup analysis of cardiac procedures showed superiority of beta-lactams in preventing superficial an

114 1 (N = 1,395; median follow-up, 106 months), superiority of bleomycin, etoposide, doxorubicin, cyclop

115 etabolic reconstructions and demonstrate the superiority of BoostGAPFILL to state-of-the-art gap fill

116 The primary objective was to assess the superiority of bOPV-IPV schedules over bOPV alone, as as

117 ween the two active intervention groups, and superiority of both intervention groups over usual care.

118 ed the futility boundaries for demonstrating superiority of both once-per-week regimens and once-ever

119 ure and performance, finding support for the superiority of both well-connected efficient and poorly

120 N: Our findings show no evidence of clinical superiority of brief guided parent-delivered CBT.

121 The primary aims were to evaluate the superiority of brodalumab over placebo at week 12 with r

122 (clear or almost clear skin), as well as the superiority of brodalumab over ustekinumab at week 12 wi

123 The superiority of C-prM-E VLPs suggests that inclusion of c

124 bition (CHAMPION) PHOENIX trial demonstrated superiority of cangrelor in reducing ischemic events at

125 tion, numerous studies have demonstrated the superiority of catheter ablation over pharmacological th

126 We found no evidence for the superiority of CBT or short-term psychoanalytical therap

127 INTERPRETATION: We found no evidence for the superiority of CBT or short-term psychoanalytical therap

128 ratory longitudinal analyses also showed the superiority of CBT over GSH-I by the 6-month (adjusted e

129 The superiority of ceftaroline fosamil was consistent across

130 No randomized trial has demonstrated superiority of chemoembolization compared with embolizat

131 eness studies-provide little evidence of the superiority of clozapine compared with other second-gene

132 stabilized by the same ligand indicates the superiority of Co.

133 This study proves the superiority of complete PVI over incomplete PVI with res

134 Randomized trial data support the superiority of coronary artery bypass grafting (CABG) su

135 ticase studies show either noninferiority or superiority of DBT compared with mammography.

136 primary effectiveness end point was met, and superiority of DCB over PTA was achieved (83.9% [188 of

137 concerning protein sequences, as well as the superiority of EBMC, SVM and LR (especially EBMC) for th

138 d investigate potential explanations for the superiority of edoxaban-ie, differences in baseline clin

139 ulticenter randomized clinical trial assumed superiority of EES for the primary endpoint, in-segment

140 e: Randomized clinical trials have shown the superiority of endovascular therapy (EVT) compared with

141 Meanwhile, DeepCode reveals the superiority of epigenomic features and their dominant ro

142 ging from equivalence between stent types to superiority of everolimus-eluting stents.

143 Serum titration established the superiority of FcMonoIgG for monitoring MFIs of de novo

144 Multivariable regression confirmed the superiority of HF-WBI in terms of patient-reported lack

145 This update aims to confirm and explain the superiority of hyperfractionated radiotherapy over other

146 Our studies demonstrate the superiority of i.n. versus i.m. vaccination in protectio

147 No trial to date has demonstrated survival superiority of IAD compared with CAD.

148 The primary objective was to demonstrate the superiority of indacaterol/glycopyrrolate versus its mon

149 s (LABAs) and may contribute to the clinical superiority of inhaled corticosteroid (ICS)/LABA combina

150 tor characteristic analysis demonstrated the superiority of KIM-1 (area under the curve [AUC]: 0.87;

151 These findings do not support the superiority of LABA + ICS compared with tiotropium + ICS

152 Overall, our data document the superiority of local production of PD-L1 mini-body by CA

153 IMPAACT) P1060 study demonstrated short-term superiority of lopinavir/ritonavir (LPV/r) over nevirapi

154 The results demonstrate no superiority of low frequencies in timing judgments but r

155 hicle for phage, and the results confirm the superiority of LP for both therapeutic and prophylactic

156 ed unblinding results in both cohorts due to superiority of LPV/r for the primary endpoint: stopping

157 nt drug action are sufficient to explain the superiority of many FDA-approved drug combinations in th

158 Collectively, our results confirmed the superiority of metronomic protocols in chemoresistant tu

159 y (mug g(-1)) assessed at 10% BTV showed the superiority of MOF-199 towards phenolic and indolic comp

160 for the field, with emphasis on showing the superiority of MOFs with respect to other solid catalyst

161 condary objective was to examine whether the superiority of MR versus RR on anxiety depended on illne

162 ase stage, and cytogenetics, with prognostic superiority of MRD negativity versus CR particularly evi

163 he sensitivity of MRI and did not affect the superiority of MRI over mammography and ultrasound.

164 Similar superiority of MV repair was obtained in patient subsets

165 The objective was to validate the superiority of nonlinear imputation of PaO2/FIO2 among m

166 aluate ERCC1 prospectively and to assess the superiority of nonplatinum therapy over platinum doublet

167 Our data suggest no superiority of novel perfusates HTK-N and TiProtec in te

168 This review also highlights the superiority of NP-based approaches over existing convent

169 The number needed to treat to show superiority of nurse-delivered treatment over other trea

170 with a non-inferiority margin of 1.0 mm(2)), superiority of OCT guidance to angiography guidance, and

171 of OCT guidance to angiography guidance, and superiority of OCT guidance to IVUS guidance, in a hiera

172 Since the trial was designed to show superiority of once-daily radiotherapy and was not power

173 We find that the superiority of one NA category over the other is context

174 ional data cannot definitively establish the superiority of one technique over another.

175 ases of different inheritance styles and the superiority of our approach over two state-of-the-art me

176 We verified the superiority of our design concept by achieving an unprec

177 ue clearing, all of which contributed to the superiority of our method.

178 ing disease gene prioritization and show the superiority of our network models and ranking algorithms

179 independent validation dataset, revealed the superiority of our newly proposed integrative approach.

180 Simulation results show the superiority of our proposed method.

181 The subgroup analyses suggest the superiority of parenteral iron over oral iron supplement

182 , which demonstrates both noninferiority and superiority of PEB treatment.

183 The study is designed to detect superiority of percutaneous drainage: a provisional samp

184 The debate around the potential superiority of quantum annealers over their classical co

185 Superiority of R-ACVBP over R-CHOP14 was not established

186 geting, recent studies have demonstrated the superiority of radiolabeled SSTR antagonists for imaging

187 are (6.0%) (P<0.05 for all comparisons); the superiority of reward-based programs was sustained throu

188 In multivariate analysis, the superiority of RYGB was primarily but not entirely expla

189 ection (STOP-IT), and results suggest global superiority of short-duration therapy for intra-abdomina

190 he results of clinical trials have shown the superiority of some of these anti-vascular endothelial g

191 The superiority of spironolactone supports a primary role of

192 risons of sstr antagonists and agonists, the superiority of sstr antagonists was demonstrated in seve

193 CALGB 49907 showed the superiority of standard therapy, which included either c

194 f acute ischemic stroke, 1 that demonstrated superiority of tenecteplase and the other that showed no

195 es exhibit good catalytic efficiency, with a superiority of the 1,2-vicinal catalyst in both cases.

196 t 3 year follow-up, the primary endpoint was superiority of the Absorb bioresorbable scaffold versus

197 Therefore, the superiority of the aforementioned specification to the o

198 However, the superiority of the BTT strategy for averting microvascul

199 size treated, did not change the comparative superiority of the BTT strategy, nor did titrating treat

200 perimental and clinical studies indicating a superiority of the closed-loop DBS to open-loop HF DBS,

201 l regioisomeric metal complexes confirms the superiority of the Cu(II) complexes over the Zn(II) anal

202 tality and speed of kill data, confirmed the superiority of the genetically mixed WT virus over any s

203 Planned interim monitoring showed the superiority of the high-dose methotrexate regimens, whic

204 t and investigator assessments supported the superiority of the high-dose therapy vs placebo.

205 rt (n=294; 6-month follow-up), demonstrating superiority of the HM3 for the trial primary end point (

206 sidered to be clinically significant to show superiority of the once-daily regimen.

207 Recent prospective trials suggest superiority of the PG regarding perioperative complicati

208 ange in mean nrCBV and nrCBF, confirming the superiority of the PRM approach.

209 Our simulation results demonstrate the superiority of the proposed MICE approach based on an in

210 r than RSM alone, verifying the adequacy and superiority of the said approach.

211 e was based on Bayesian probabilities of the superiority of the treatment over control.

212 eric biologic mesh, little data exist on the superiority of these materials in the setting of high-ri

213 These findings do not support superiority of this program among patients with motor st

214 The superiority of this technique can open an avenue to esta

215 studies and clinical trials, suggesting the superiority of transendocardial stem cell injection beca

216 erpotential of 96 mV, further confirming the superiority of Tri-Ag-NPs as a catalyst for CO2RR toward

217 rted by very-low-quality evidence except for superiority of TZDs over vitamin E on improving steatosi

218 Moreover, the potential superiority of YSNs for these applications is also highl

219 One drug demonstrated superiority on an exploratory secondary end point, 2 sho

220 In this multicentre, parallel group, superiority, open-label, blinded-endpoint, randomised co

221 with the renin inhibitor aliskiren (to test superiority or at least noninferiority) and with the com

222 e most likely mechanism of AR160 therapeutic superiority over ABX or rituximab alone.

223 nd dexamethasone is well-tolerated and shows superiority over active control for the prevention of ch

224 nd dexamethasone is well tolerated and shows superiority over active control for the prevention of ch

225 produces moderate to large effects and shows superiority over control/comparison conditions.

226 Trabectedin plus doxorubicin did not show superiority over doxorubicin alone as first-line treatme

227 CAP's superiority over EUC at the end of treatment was largely

228 HAP's superiority over EUC at the end of treatment was largely

229 Perceived superiority over PET/CT was identified as the strongest

230 Lisdexamfetamine demonstrated superiority over placebo on the log-rank test (chi21, 40

231 ze = .4) demonstrated antipsychotic efficacy superiority over placebo on the primary end point.

232 completer samples, GSK561679 failed to show superiority over placebo on the primary outcome of chang

233 ciency of tasks and establishing competitive superiority over solitary species.

234 on while producing alignments and showed its superiority over the existing methods.

235 ), and also meeting criteria for statistical superiority (P < .001).

236 -inferiority (p=8.82 x 10(-16)) and post-hoc superiority (p=0.023) were met.

237 natide to placebo (P<0.001) but did not show superiority (P=0.81).

238 We did this superiority, placebo-controlled randomised trial in 19 f

239 Double-blind, superiority randomized clinical trial of infants and chi

240 4; P < .001 for noninferiority; P < .001 for superiority; rate difference, -130.31 episodes per 100 P

241 3; P < .001 for noninferiority; P < .001 for superiority; rate difference, -61.94 episodes per 100 PY

242 Prespecified criteria for superiority required a hazard ratio of 0.56 or less with

243 (modified intention to treat [mITT] for the superiority safety analysis and mITT and per protocol fo

244 nd thereafter), parallel-group, head-to-head superiority study (EXXELERATE), eligible patients from 1

245 andomized, double-blind, placebo-controlled, superiority study was performed between January 1, 2011,

246 In this randomised, controlled, open-label, superiority study, we recruited hospitalised adults aged

247 nt, but no specific approach has shown clear superiority, suggesting a combination of re-nourishment

248 art approaches developed for this problem, a superiority that is reflected particularly in the absolu

249 o unclear why some drugs showing statistical superiority to placebo in one trial may fail to do so in

250 ized controlled trials (RCTs), demonstrating superiority to placebo or relevant control treatments, a

251 nium showed not only noninferiority but also superiority to salmeterol-fluticasone in reducing the an

252 as established (upper 95% CI <1.25), but its superiority to tamoxifen was not (p=0.49).

253 Compound 1 also showed clear superiority to the cyclooxygenase inhibitors diclofenac

254 he use of functional measures and proven its superiority to the maximal LA volume, they have still no

255 The UHPLC method showed its superiority to the MBA in determining the active vitamin

256 alysis of RNA sequencing data and showed its superiority to three existing methods for differential e

257 However, there is no evidence of its superiority to traditional dietary advice for these pati

258 f neutralizing antibodies, demonstrating its superiority to vaccines adjuvanted by monophosphoryl lip

259 matic, observer-blind, randomised controlled superiority trial (IMPACT) at 15 National Health Service

260 open-label, two-arm individually randomized superiority trial among HIV-seronegative women at three

261 We conducted a randomized, double-blind, superiority trial at 5 US emergency departments.

262 group, observer-blind, randomised controlled superiority trial at eight community sites in two region

263 en-label, three-group, randomised controlled superiority trial at four sites in western Kenya with hi

264 e did an open-label, randomised, controlled, superiority trial at two hospitals in the Kathmandu vall

265 Multicenter 1:1 randomized superiority trial comparing coils with usual care at 10

266 We did a randomised, multicentre, superiority trial comparing transradial against transfem

267 Parallel, randomized, open-label, phase 3 superiority trial conducted at 16 Italian sites.

268 For other risk levels, randomized superiority trial designs are recommended; noninferiorit

269 pragmatic, multicenter, randomized clinical superiority trial in 10 intensive care units (ICUs) at 1

270 Multicenter, double-blind, randomized superiority trial in 5 US emergency departments among ou

271 ingle-blind, randomised, controlled, phase 2 superiority trial of adult patients with low-risk or Int

272 Multicenter, randomized clinical superiority trial recruiting participants from 21 center

273 ternational, open-label, randomised, phase 3 superiority trial that enrolled women aged 18 years or o

274 open-label, active-controlled, multicentre, superiority trial to compare REG1 with bivalirudin at 22

275 d, controlled, double-blind, parallel-group, superiority trial was done in 18 hospitals across Europe

276 multicentre, randomised, placebo-controlled superiority trial with four parallel groups at 13 memory

277 In this superiority trial with two-sided significance testing, w

278 -blind, phase 3, non-inferiority with nested superiority trial, adult Asian patients with Pneumonia O

279 In this phase 3 randomised controlled superiority trial, we included general surgery adult inp

280 ized, prospective, double-masked, controlled superiority trial.

281 8 is an open-label, prospective, randomized, superiority trial.

282 trial was an open-label, phase 3, randomised superiority trial.

283 with biologic agents, nonstrategy trials, or superiority trials did not improve surrogacy.

284 molecular state changes, and demonstrate its superiority using independent datasets.

285 Treatment specifications; primary end point; superiority versus noninferiority design assumptions, in

286 terval 76%-91%) met the primary objective of superiority versus the historical control (70%).

287 established, 2-sided statistical testing for superiority was conducted.

288 eriority was established, a 1-sided test for superiority was conducted.

289 The primary safety end point was met, and superiority was demonstrated; freedom from a primary saf

290 fference was positive and greater than zero, superiority was indicated.

291 Although superiority was not shown, the noninferiority hypothesis

292 or higher; if non-inferiority was achieved, superiority was to be concluded if the lower limit of th

293 secondary angiographic endpoint (powered for superiority) was in-segment percent diameter stenosis of

294 nd point, tested for both noninferiority and superiority, was a composite of cardiac death, myocardia

295 rcentage points for the risk difference) and superiority, was target-lesion failure (cardiac death, t

296 capture the complex mixed feelings of proud superiority when "looking down upon" and acting harshly

297 Superiority with a low-dose DCB for femoropopliteal inte

298 riority with a one-sided alpha of 0.025, and superiority with a two-sided alpha of 0.025.

299 0.97; P<0.001 for noninferiority, P=0.02 for superiority) with no statistical evidence of heterogenei

300 visional group (31.6% vs. 38.6%, p=0.002 for superiority), with no difference in binary restenosis ra